Urinary excretion of homocysteine thiolactone and the risk of acute myocardial infarction in coronary artery disease patients: the WENBIT trial.

ABSTRACT:

Objectives

No individual homocysteine (Hcy) metabolite has been studied as a risk marker for coronary artery disease (CAD). Our objective was to examine Hcy-thiolactone, a chemically reactive metabolite generated by methionyl-tRNA synthetase and cleared by the kidney, as a risk predictor of incident acute myocardial infarction (AMI) in the Western Norway B-Vitamin Intervention Trial.

Design

Single centre, prospective double-blind clinical intervention study, randomized in a 2 × 2 factorial design.

Subjects and methods

Patients with suspected CAD (n = 2049, 69.8% men; 61.2-year-old) were randomized to groups receiving daily (i) folic acid (0.8 mg)/vitamin B₁₂ (0.4 mg)/vitamin B₆ (40 mg); (ii) folic acid/vitamin B₁₂ ; (iii) vitamin B

SUBMITTER: Borowczyk K 

PROVIDER: S-EPMC6378604 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature